Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00921115 · ClinicalTrials.gov registry record · Phase 2
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00921115 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 42 participants.
The verdict
NCT00921115, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.
Interventions
- DRUG Fulvestrant
- DRUG Anastrazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-05 |
| Est. Completion | 2023-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00921115
The ClinicalTrials.gov registry entry for NCT00921115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT00921115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00921115 about?
NCT00921115 is a clinical study titled "Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.". This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.
What is the current status of trial NCT00921115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2009-05. Estimated completion is 2023-03-20.
What interventions are being tested in trial NCT00921115?
The interventions under investigation include: Fulvestrant (DRUG), Anastrazole (DRUG).
Who is sponsoring clinical trial NCT00921115?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.